Canntab Therapeutics Limited reported earnings results for the full year ended May 31, 2022. For the full year, the company reported net loss was CAD 3.69 million compared to CAD 4.42 million a year ago. Basic loss per share from continuing operations was CAD 0.1 compared to CAD 0.13 a year ago.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
0.005 CAD | -.--% | -.--% | -.--% |
Apr. 15 | Canntab Therapeutics Limited announced that it expects to receive CAD 0.1 million in funding | CI |
2023 | Canntab Therapeutics Limited Provide an Update on Product Delivery | CI |
1st Jan change | Capi. | |
---|---|---|
-.--% | 142K | |
-15.13% | 4.51B | |
-9.75% | 3.15B | |
+2.14% | 3.1B | |
-6.82% | 2.42B | |
+47.87% | 1.97B | |
+0.09% | 1.65B | |
-7.89% | 1.68B | |
-12.97% | 1.53B | |
+33.40% | 1.38B |
- Stock Market
- Equities
- PILL Stock
- News Canntab Therapeutics Limited
- Canntab Therapeutics Limited Reports Earnings Results for the Full Year Ended May 31, 2022